Belgian Multidiscplinary Immunotoxicity Board (BITOX)
Aim: share experiences, standardize approach for irAEs and find clinically relevant research questions
Online questionnaire
approx. 5 minutes to fill in case details
Click here to fill in case details
via smartphone
Questions handled
- Diagnosis and management of severe immune related adverse events
- Starting immunotherapy in ‘dysimmune’ patients
- transplant patients
- patients with chronic (viral) infections
- patients with autoimmune disorders
- immunosuppressed patients
- rechallenge after irAE
- other
Bimonthly virtual meeting via Teams
- onco/hematologists, organspecialists and interested healthcare professionals
- Timing: 1st and 3rd Monday of each month 16:00-17:00
- if you are unable to attend, the case can still be discussed with a written recommendation provided
Abbrevations
IT: Immunotherapy for solid or hematological cancers
irAE: Immune Related Adverse Event
ICI: Immune Checkpoint Inhibition
Dysimmunity: having an characteristic which might influence IT outcome (eg underlying auto immune disease, having previous irAE, chronic viral infection, severe allergy, ….)
